Journal of gastroenterology and hepatology
-
J. Gastroenterol. Hepatol. · Mar 2008
Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
To investigate the clinical characteristics and survival outcomes of a large cohort of hepatocellular carcinoma (HCC) patients treated at a single institute in a hepatitis B virus (HBV)-endemic area. ⋯ The results of this study will be helpful in determining the survival outcomes and treatment strategies for HCC patients in HBV-endemic areas.
-
J. Gastroenterol. Hepatol. · Mar 2008
Editorial CommentPublications from China: the sleeping giant awakens.
-
J. Gastroenterol. Hepatol. · Feb 2008
ReviewAntituberculosis drug-induced hepatotoxicity: concise up-to-date review.
The cornerstone of tuberculosis management is a 6-month course of isoniazid, rifampicin, pyrazinamide and ethambutol. Compliance is crucial for curing tuberculosis. Adverse effects often negatively affect the compliance, because they frequently require a change of treatment, which may have negative consequences for treatment outcome. ⋯ Still, it is difficult to predict what patient will develop hepatotoxicity during tuberculosis treatment. The exact mechanism of antituberculosis drug-induced hepatotoxicity is unknown, but toxic metabolites are suggested to play a crucial role in the development, at least in the case of isoniazid. Priorities for future studies include basic studies to elucidate the mechanism of antituberculosis drug-induced hepatotoxicity, genetic risk factor studies and the development of shorter and safer tuberculosis drug regimens.
-
J. Gastroenterol. Hepatol. · Dec 2007
Randomized Controlled TrialEfficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
Dioctahedral smectite (DS) is natural adsorbent clay useful in treating acute diarrhea. The aim of this study was to determine DS efficacy on patients with diarrhea-predominant irritable bowel syndrome (D-IBS in a phase III-, 8-week-randomized, double-blind, placebo-controlled trial. ⋯ DS seems acceptable to treat D-IBS patients, particularly for pain-related symptoms.